Skip to main content
PharmLaw

Teva Reaches Preliminary Settlement in Multistate Generic Drug Price-Fixing Litigation

Edited by 

Key Takeaways: 

  • Teva Pharmaceutical Industries and its Actavis subsidiary have reached an agreement in principle to resolve longstanding antitrust litigation brought by 45 states, Washington, DC, and 2 US territories over alleged generic drug price-fixing.¹,²
  • The states allege that Teva and competing manufacturers coordinated pricing and market allocation, contributing to substantial price increases for numerous generic medications, including some increases exceeding 1000%.¹
  • Although settlement terms have not been disclosed, the agreement represents a significant development in multistate pharmaceutical antitrust enforcement and highlights ongoing compliance risks associated with competitor communications, pricing practices, and market allocation.¹,²

Teva Pharmaceutical Industries has reached a preliminary settlement with a coalition of state attorneys general in a long-running antitrust lawsuit alleging that the manufacturer conspired with competitors to inflate generic drug prices and limit competition in the US pharmaceutical market.¹

On November 16, 2026, Chief Judge Michael P. Shea of the US District Court for the District of Connecticut stayed proceedings against Teva after the parties informed the court that they had reached an agreement in principle. The proposed resolution involves 45 states, Washington, DC, and two US territories, with Connecticut leading the litigation.¹,²

The financial terms and any additional settlement conditions have not been publicly disclosed. The agreement remains preliminary, and the court's decision to stay proceedings does not constitute a finding that Teva violated antitrust law.¹

Multistate Lawsuit Alleges Coordinated Generic Drug Pricing

The litigation stems from allegations that Teva and other generic pharmaceutical manufacturers engaged in coordinated pricing and market allocation practices beginning in 2012.

According to the states, manufacturers allegedly agreed to preserve their respective market shares while increasing prices on numerous generic medications. The complaint contends that these arrangements reduced competition among manufacturers that otherwise would have been expected to negotiate and establish prices independently.¹

The states alleged that Teva substantially increased prices on approximately 112 generic drugs and coordinated with competitors on price increases involving at least 86 products. Some of the alleged increases exceeded 1000%, particularly during 2013 and 2014.¹

The allegations form part of a broader investigation into whether generic pharmaceutical manufacturers engaged in agreements to stabilize market shares and raise prices rather than competing independently.

The conduct described in the complaint remains alleged, and the preliminary settlement does not establish liability.

Agreement in Principle Pauses Federal Proceedings

According to Reuters, Judge Shea placed the litigation against Teva on hold following notification that the parties had reached an agreement in principle.¹

Bloomberg Law reported that the agreement also involves Teva's Actavis subsidiary, which the company acquired as part of its 2016 purchase of Allergan's generics business.²

The stay provides time for the parties to finalize the settlement, but it does not itself resolve the litigation or establish the agreement's terms.

As of November 18, 2026, the parties had not publicly disclosed whether the resolution would include monetary payments, changes to business practices, compliance monitoring, or other obligations.

Teva and the Connecticut Attorney General's Office did not immediately respond to requests for comment from Reuters.¹

Antitrust Allegations Focus on Pricing and Market Allocation

The case raises legal questions under federal and state antitrust laws, particularly regarding agreements between competing manufacturers.

Under Section 1 of the Sherman Antitrust Act, agreements among competitors to fix prices or allocate markets are generally considered per se unlawful, meaning courts ordinarily do not require a separate assessment of their competitive effects once the prohibited agreement is established.

In pharmaceutical markets, potential antitrust concerns can arise when competing manufacturers coordinate pricing decisions, exchange competitively sensitive information, or agree to avoid competing for particular customers or products.

The states' allegations against Teva center on whether manufacturers used communications and understandings with competitors to maintain market positions and increase generic drug prices.¹

These allegations differ from lawful independent pricing decisions or legitimate commercial arrangements that do not involve prohibited coordination.

For pharmaceutical manufacturers, the litigation illustrates the importance of maintaining independent pricing strategies and implementing controls governing communications with competitors.

Settlement Adds to Broader Generic Drug Antitrust Litigation

The Teva agreement is part of a larger series of lawsuits brought by state attorneys general involving alleged anticompetitive conduct in the generic pharmaceutical industry.

The litigation has targeted numerous manufacturers and individuals accused of participating in arrangements that allegedly affected the pricing and availability of widely prescribed medications.

According to Reuters, Judge Shea is overseeing two additional antitrust lawsuits brought by state attorneys general involving generic drug manufacturers.¹

The broader litigation illustrates how pharmaceutical pricing practices can become the subject of coordinated enforcement across multiple jurisdictions, particularly when alleged conduct affects drug purchasers, health plans, pharmacies, and government health care programs.

Although the proposed Teva resolution may narrow the litigation against the settling parties, it does not necessarily resolve claims against other manufacturers involved in related proceedings.

Compliance Implications for Pharmaceutical Manufacturers

The preliminary settlement highlights several compliance considerations for pharmaceutical manufacturers operating in competitive markets.

Antitrust compliance programs should address risks involving:

  • Competitor communications: Establishing clear restrictions on discussions of current or future prices, pricing strategies, customer relationships, and market allocation.
  • Pricing independence: Ensuring that decisions regarding price increases, discounts, and commercial terms are made independently rather than through agreements with competitors.
  • Trade association participation: Monitoring industry meetings and communications to prevent inappropriate exchanges of competitively sensitive information.
  • Internal documentation: Maintaining records that support legitimate business justifications for pricing decisions.
  • Employee training and reporting: Providing antitrust training and mechanisms for employees to report potentially improper competitor interactions.

For manufacturers involved in mergers and acquisitions, the litigation also underscores the importance of assessing historical antitrust exposure and maintaining compliance oversight across acquired businesses.

The involvement of Teva and its Actavis subsidiary illustrates how longstanding allegations may remain relevant years after corporate transactions have occurred.

Potential Implications for Drug Pricing and Competition

Generic drug competition is an important component of prescription drug affordability because multiple manufacturers producing therapeutically equivalent products can create opportunities for lower prices.

Alleged coordination among manufacturers can undermine those competitive pressures if companies agree to maintain prices or avoid competing for market share.

The states' allegations therefore raise broader questions about how antitrust enforcement can address pricing practices that may affect pharmacies, payers, government programs, and patients.

However, the financial effects of the proposed Teva settlement cannot yet be assessed because the agreement's terms remain undisclosed.

Whether the resolution includes consumer restitution, payments to states, or prospective compliance obligations will be important in evaluating its practical significance.

Looking Ahead

The preliminary settlement represents a significant procedural development in one of the pharmaceutical industry's longstanding antitrust disputes.

The next steps will depend on whether Teva and the participating states finalize their agreement and disclose its terms. Any proposed financial payments, compliance requirements, or other remedies could provide additional insight into how multistate authorities are approaching resolution of generic drug price-fixing allegations.

For pharmaceutical manufacturers and compliance professionals, the case reinforces the importance of independent pricing decisions, appropriate safeguards around competitor communications, and continued monitoring of antitrust enforcement developments.

Although the agreement may bring Teva closer to resolving the states' claims, the broader litigation underscores the continuing legal exposure associated with alleged coordination in pharmaceutical markets.

References

  1. Stempel J. Teva settles US states' drug price-fixing case. Reuters. Published November 16, 2026. Accessed November 18, 2026. https://www.investing.com/news/stock-market-news/teva-settles-us-states-drug-pricefixing-case-5030548 
  2. Arcieri K. Teva inks settlement in states' generic drug price-fixing suit. Bloomberg Law. Published November 17, 2026. Accessed November 18, 2026. https://news.bloomberglaw.com/health-law-and-business/teva-inks-settlement-in-states-generic-drug-price-fixing-suit 
  3. Eslinger B. Teva, Actavis near deal in states' generic-drug pricing MDL. Law360. Published November 16, 2026. Accessed November 18, 2026. https://www.law360.com/articles/2550558